Oncogenic ILK, tumor suppression and all that JNK

Cell Cycle

Volumn 8, Issue 24, 2009, Pages 4060-4066

  Durbin, Adam David ^a,b,c   Hannigan, Gregory Edward ^d   Malkin, David ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

ILK; JNK; Oncogene; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; INTEGRIN LINKED KINASE; INTEGRIN LINKED KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTRANSFERASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; HUMAN; NONHUMAN; ONCOGENE; REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

HARNESS;

EID: 74849132460     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.24.10093     Document Type: Review

References (103)

1. Radisky DC, Stallings-Mann M, Hirai Y, Bissell MJ. Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol 2009; 10:29-34.
2. Robson EJ, He SJ, Eccles MR. A PANorama of PAX genes in cancer and development. Nat Rev Cancer 2006; 6:52-62.
3. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244:217-21.
4. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D, et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007; 21:1731-46.
5. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008; 22:449-62.
6. Fleischmann A, Jochum W, Eferl R, Witowsky J, Wagner EF. Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell 2003; 4:477-82.
7. McDonald SL, Silver A. The opposing roles of Wnt-5a in cancer. Br J Cancer 2009; 101:209-14.
8. Durbin AD, Somers GR, Forrester M, Pienkowska M, Hannigan GE, Malkin D. JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest 2009; 119:1558-70.
9. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5:51-63.
10. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase-essential roles in physiology and cancer biology. J Cell Sci 2008; 121:3121-32.
11. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta1-integrin-linked protein kinase. Nature 1996; 379:91-6.
12. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998; 95:11211-6.
13. Pasquali C, Bertschy-Meier D, Chabert C, Curchod ML, Arod C, Booth R, et al. A chemical proteomics approach to phosphatidylinositol 3-kinase signaling in macrophages. Mol Cell Proteomics 2007; 6:1829-41.
14. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000; 97:3207-12.
15. Kumar AS, Naruszewicz I, Wang P, Leung-Hagesteijn C, Hannigan GE. ILKAP regulates ILK signaling and inhibits anchorage-independent growth. Oncogene 2004; 23:3454-61.
16. Legate KR, Montanez E, Kudlacek O, Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006; 7:20-31.
17. D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, et al. The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 2000; 275:32649-57.
18. Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, et al. Regulation of protein kinase B/ Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001; 276:27462-9.
19. Zhang Y, Ikegami T, Honda A, Miyazaki T, Bouscarel B, Rojkind M, et al. Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. Hepatology 2006; 44:612-22.
20. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, et al. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 2007; 67:684-94.
21. Leung-Hagesteijn C, Hu MC, Mahendra AS, Hartwig S, Klamut HJ, Rosenblum ND, et al. Integrin-linked kinase mediates bone morphogenetic protein 7-dependent renal epithelial cell morphogenesis. Mol Cell Biol 2005; 25:3648-57.
22. Zhang X, Li Y, Huang Q, Wang H, Yan B, Dewhirst MW, et al. Increased resistance of tumor cells to hyperthermia mediated by integrin-linked kinase. Clin Cancer Res 2003; 9:1155-60.
23. Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3 and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005; 65:1497-504.
24. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/ Akt activation and cell survival. Cancer Res 2006; 66:393-403.
25. Zervas CG, Gregory SL, Brown NH. Drosophila integrin-linked kinase is required at sites of integrin adhesion to link the cytoskeleton to the plasma membrane. J Cell Biol 2001; 152:1007-18.
26. Sakai T, Li S, Docheva D, Grashoff C, Sakai K, Kostka G, et al. Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion and controlling actin accumulation. Genes Dev 2003; 17:926-40.
27. Mackinnon AC, Qadota H, Norman KR, Moerman DG, Williams BD. C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes. Curr Biol 2002; 12:787-97.
28. Yasunaga T, Kusakabe M, Yamanaka H, Hanafusa H, Masuyama N, Nishida E. Xenopus ILK (integrin-linked kinase) is required for morphogenetic movements during gastrulation. Genes Cells 2005; 10:369-79.
29. Terpstra L, Prud'homme J, Arabian A, Takeda S, Karsenty G, Dedhar S, et al. Reduced chondrocyte proliferation and chondrodysplasia in mice lacking the integrin-linked kinase in chondrocytes. J Cell Biol 2003; 162:139-48.
30. Belvindrah R, Nalbant P, Ding S, Wu C, Bokoch GM, Muller U. Integrin-linked kinase regulates Bergmann glial differentiation during cerebellar development. Mol Cell Neurosci 2006; 33:109-25.
31. Mills J, Niewmierzycka A, Oloumi A, Rico B, St-Arnaud R, Mackenzie IR, et al. Critical role of integrin-linked kinase in granule cell precursor proliferation and cerebellar development. J Neurosci 2006; 26:830-40.
32. Friedrich EB, Liu E, Sinha S, Cook S, Milstone DS, MacRae CA, et al. Integrin-linked kinase regulates endothelial cell survival and vascular development. Mol Cell Biol 2004; 24:8134-44.
33. Liu E, Sinha S, Williams C, Cyrille M, Heller E, Snapper SB, et al. Targeted deletion of integrin-linked kinase reveals a role in T-cell chemotaxis and survival. Mol Cell Biol 2005; 25:11145-55.
34. Gkretsi V, Mars WM, Bowen WC, Barua L, Yang Y, Guo L, et al. Loss of integrin linked kinase from mouse hepatocytes in vitro and in vivo results in apoptosis and hepatitis. Hepatology 2007; 45:1025-34.
35. Nakrieko KA, Welch I, Dupuis H, Bryce D, Pajak A, St. Arnaud R, et al. Impaired hair follicle morphogenesis and polarized keratinocyte movement upon conditional inactivation of integrin-linked kinase in the epidermis. Mol Biol Cell 2008; 19:1462-73.
36. Lorenz K, Grashoff C, Torka R, Sakai T, Langbein L, Bloch W, et al. Integrin-linked kinase is required for epidermal and hair follicle morphogenesis. J Cell Biol 2007; 177:501-13.
37. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol 2008; 129:705-33.
38. Lu H, Hesse M, Peters B, Magin TM. Type II keratins precede type I keratins during early embryonic development. Eur J Cell Biol 2005; 84:709-18.
39. Gkretsi V, Apte U, Mars WM, Bowen WC, Luo JH, Yang Y, et al. Liver-specific ablation of integrin-linked kinase in mice results in abnormal histology, enhanced cell proliferation, and hepatomegaly. Hepatology 2008.
40. Apte U, Gkretsi V, Bowen WC, Mars WM, Luo JH, Donthamsetty S, et al. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology 2009.
41. Gkretsi V, Bowen WC, Yang Y, Wu C, Michalopoulos GK. Integrin-linked kinase is involved in matrix-induced hepatocyte differentiation. Biochem Biophys Res Commun 2007; 353:638-43.
42. Miller MG, Naruszewicz I, Kumar AS, Ramlal T, Hannigan GE. Integrin-linked kinase is a positive mediator of L6 myoblast differentiation. Biochem Biophys Res Commun 2003; 310:796-803.
43. Huang Y, Li J, Zhang Y, Wu C. The roles of integrin-linked kinase in the regulation of myogenic differentiation. J Cell Biol 2000; 150:861-72.
44. Niewmierzycka A, Mills J, St-Arnaud R, Dedhar S, Reichardt LF. Integrin-linked kinase deletion from mouse cortex results in cortical lamination defects resembling cobblestone lissencephaly. J Neurosci 2005; 25:7022-31.
45. Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, Goicoechea S, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem 1998; 273:528-36.
46. White DE, Cardiff RD, Dedhar S, Muller WJ. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 2001; 20:7064-72.
47. Assi K, Mills J, Owen D, Ong C, St. Arnaud R, Dedhar S, et al. Integrin-linked kinase regulates cell proliferation and tumor growth in murine colitis-associated carcinogenesis. Gut 2008; 57:931-40.
48. Okamura M, Yamaji S, Nagashima Y, Nishikawa M, Yoshimoto N, Kido Y, et al. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007; 38:1081-91.
49. Takanami I. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 2005; 5:1.
50. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003; 9:4409-14.
51. Chen P, Shen WZ, Karnik P. Suppression of malignant growth of human breast cancer cells by ectopic expression of integrin-linked kinase. Int J Cancer 2004; 111:881-91.
52. Cordes N. Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity. Cancer Res 2004; 64:5683-92.
53. Hess F, Estrugo D, Fischer A, Belka C, Cordes N. Integrin-linked kinase interacts with caspase-9 and -8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells. Oncogene 2007; 26:1372-84.
54. Eke I, Sandfort V, Storch K, Baumann M, Roper B, Cordes N. Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radio-sensitization in vitro. Int J Radiat Biol 2007; 83:793-802.
55. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 2005; 4:1146-56.
56. Ahmed N, Riley C, Oliva K, Stutt E, Rice GE, Quinn MA. Integrin-linked kinase expression increases with ovarian tumor grade and is sustained by peritoneal tumor fluid. J Pathol 2003; 201:229-37.
57. Ahmed N, Oliva K, Rice GE, Quinn MA. Cell-free 59 kDa immunoreactive integrin-linked kinase: a novel marker for ovarian carcinoma. Clin Cancer Res 2004; 10:2415-20.
58. Papachristou DJ, Gkretsi V, Rao UN, Papachristou GI, Papaefthymiou OA, Basdra EK, et al. Expression of integrin-linked kinase and its binding partners in chondrosarcoma: Association with prognostic significance. Eur J Cancer 2008.
59. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007; 14:719-29.
60. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C, Dedhar S. alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 2003; 22:1688-702.
61. Intaraprasong P, Assi K, Owen DA, Huntsman DG, Chung SW, Scudamore CH, et al. Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res 2007; 27:4371-6.
62. Plante I, Cyr DG, Charbonneau M. Involvement of the integrin-linked kinase pathway in hexachlorobenzene-induced gender-specific rat hepatocarcinogenesis. Toxicol Sci 2005; 88:346-57.
63. Su JM, Wang LY, Liang YL, Zha XL. Role of cell adhesion signal molecules in hepatocellular carcinoma cell apoptosis. World J Gastroenterol 2005; 11:4667-73.
64. Chung DH, Lee JI, Kook MC, Kim JR, Kim SH, Choi EY, et al. ILK (beta1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumor. Virchows Arch 1998; 433:113-7
65. Haase M, Gmach CC, Eke I, Hehlgans S, Baretton GB, Cordes N. Expression of integrin-linked kinase is increased in differentiated cells. J Histochem Cytochem 2008; 56:819-29.
66. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103:239-52.
67. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3:859-68.
68. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9:537-49.
69. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4:131-6.
70. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996; 15:2760-70.
71. Nikolopoulos SN, Turner CE. Integrin-linked kinase (ILK) binding to paxillin LD1 motif regulates ILK localization to focal adhesions. J Biol Chem 2001; 276:23499-505.
72. Tamura S, Toriumi S, Saito J, Awano K, Kudo TA, Kobayashi T. PP2C family members play key roles in regulation of cell survival and apoptosis. Cancer Sci 2006; 97:563-7.
73. Troussard AA, Costello P, Yoganathan TN, Kumagai S, Roskelley CD, Dedhar S. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 2000; 19:5444-52.
74. Quelo I, Gauthier C, Hannigan GE, Dedhar S, St-Arnaud R. Integrin-linked kinase regulates the nuclear entry of the c-Jun coactivator alpha-NAC and its coactivation potency. J Biol Chem 2004; 279:43893-9.
75. McDonald PC, Dedhar S, Keller C. Integrin-linked kinase: both Jekyll and Hyde in rhabdomyosarcoma. J Clin Invest 2009; 119:1452-5.
76. Schutte J, Minna JD, Birrer MJ. Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci USA 1989; 86:2257-61.
77. Mauro A, Ciccarelli C, De Cesaris P, Scoglio A, Bouche M, Molinaro M, et al. PKCalpha-mediated ERK, JNK and p38 activation regulates the myogenic program in human rhabdomyosarcoma cells. J Cell Sci 2002; 115:3587-99.
78. De Giovanni C, Lollini PL, Dolcetti R, Landuzzi L, Nicoletti G, D'Andrea E, et al. Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells. Br J Cancer 1993; 67:674-9.
79. Teng DH, Perry WL, 3rd, Hogan JK, Baumgard M, Bell R, Berry S, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997; 57:4177-82.
80. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27:6245-51.
81. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev 2003; 17:629-37.
82. Wang L, Pan Y, Dai JL. Evidence of MKK4 prooncogenic activity in breast and pancreatic tumors. Oncogene 2004; 23:5978-85.
83. Uhlirova M, Jasper H, Bohmann D. Non-cellautonomous induction of tissue overgrowth by JNK/ Ras cooperation in a Drosophila tumor model. Proc Natl Acad Sci USA 2005; 102:13123-8.
84. Uhlirova M, Bohmann D. JNK- and Fos-regulated Mmp1 expression cooperates with Ras to induce invasive tumors in Drosophila. EMBO J 2006; 25:5294-304.
85. Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, et al. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 2007; 26:2658-66.
86. Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 1997; 16:2634-45.
87. Strle K, Broussard SR, McCusker RH, Shen WH, LeCleir JM, Johnson RW, et al. C-jun N-terminal kinase mediates tumor necrosis factor-alpha suppression of differentiation in myoblasts. Endocrinology 2006; 147:4363-73.
88. Alter J, Rozentzweig D, Bengal E. Inhibition of myoblast differentiation by tumor necrosis factor alpha is mediated by c-Jun N-terminal kinase 1 and leukemia inhibitory factor. J Biol Chem 2008; 283:23224-34.
89. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, et al. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 2005; 11:6065-74.
90. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NFkappaB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006; 103:10544-51.
91. Sancho R, Nateri AS, de Vinuesa AG, Aguilera C, Nye E, Spencer-Dene B, et al. JNK signalling modulates intestinal homeostasis and tumorigenesis in mice. EMBO J 2009; 28:1843-54.
92. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 2004; 15:713-25.
93. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006; 124:601-13.
94. Yao K, Cho YY, Bode AM, Vummenthala A, Park JG, Liu K, et al. A selective small-molecule inhibitor of c-Jun N-terminal kinase 1. FEBS Lett 2009; 583:2208-12.
95. Angell RM, Atkinson FL, Brown MJ, Chuang TT, Christopher JA, Cichy-Knight M, et al. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett 2007; 17:1296-301.
96. Muranyi AL, Dedhar S, Hogge DE. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol 2009; 37:450-60.
97. Liu J, Costello PC, Pham NA, Pintillie M, Jabali M, Sanghera J, et al. Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model. J Thorac Oncol 2006; 1:771-9.
98. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003; 22:5885-96.
99. Marotta A, Tan C, Gray V, Malik S, Gallinger S, Sanghera J, et al. Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene 2001; 20:6250-7.
100. Song Z, Tong C, Liang J, Dockendorff A, Huang C, Augenlicht LH, et al. JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol 2007; 560:95-100.
101. Katagiri C, Negishi K, Hibino T. c-JUN N-terminal kinase-1 (JNK1) but not JNK2 or JNK3 is involved in UV signal transduction in human epidermis. J Dermatol Sci 2006; 43:171-9.
102. Hirano H, Tabuchi Y, Kondo T, Zhao QL, Ogawa R, Cui ZG, et al. Analysis of gene expression in apoptosis of human lymphoma U937 cells induced by heat shock and the effects of alpha-phenyl N-tertbutylnitrone (PBN) and its derivatives. Apoptosis 2005; 10:331-40.
103. Lafarge S, Sylvain V, Ferrara M, Bignon YJ. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001; 20:6597-606.